Most of the companies in the healthcare field around the world tend to conduct research for developing cures for life-threatening diseases. In this series, Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) has also made an announcement with regard to two new sites for the Neuro-Spinal Scaffold.
Insights On The Matter:
Reports claim that NVIV has decided to add Froedtert & the Medical College of Wisconsin as the new trial sites for the ongoing IDE pilot study of the company. Thousands of patients around the world suffer from acute spinal cord injury. NVIV’s Neuro-Spinal Scaffold project focuses on such patients. At present, Froedtert Hospital has facilities only for adult Level 1 trauma center in eastern Wisconsin. It is the only hospital, with these many amenities; hence, patients with issues in the spinal cord from other areas like Wisconsin, northern Michigan, and northern Illinois also come here on referral basis.
Renowned neurosurgeon, Shekar Kurpad, has been appointed as the Principal Investigator at the site. He holds a Ph.D. and MD degree and works at MCW as the professor of neurosurgery. Along with this, Mr. Kurpad is also the director of Spine Surgery Fellowship and Spinal Cord Injury Center at Froedtert Hospital. The management of NVIV was very excited to announce his name. While talking to reporters, Mr. Kurpad said that it was a first-of-its-kind study; hence, he was feeling privileged to be a part of it.
Reports claim that the first patient was enrolled in October 2014, while the second patient on January 22, 2015. Both of them agreed to take part in the study. The management of the company is happy, with the current proceedings. As per the reports, NVIV’s CEO, Mark Perri, said that the company would achieve its objectives under solid leadership of MCW and Dr. Kurpad. He also clarified that the company would continue to take such steps in future as well.